Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Research results from University of Mississippi Medical Center update knowledge of gene therapy
May 29th, 2008
"Methylamine dehydrogenase (MADH) contains the protein-derived cofactor tryptophan tryptophylquinone (TTQ) which is generated by the posttranslational modification of two endogenous tryptophan residues. The modifications are incorporation of two oxygens into one tryptophan side chain and the covalent cross-linking of that side chain to a second tryptophan residue," scientists writing in the journal Biochemistry report. "This process requires at least one accessory gene, mauG. Inactivation of mauG in vivo results in production of an inactive 119 kDa tetrameric alpha(2)beta(2) protein precursor of MADH with incompletely synthesized TTQ. This precursor can be...
Source: Gene Therapy Weekly (2008-05-29)
|
